Europe
DBV announced positive topline results from its Phase III PEPITES trial evaluating the long-term efficacy and safety of investigational Viaskin Peanut in peanut-allergic children aged 4 to 11 years.
Atriva Therapeutics GmbH, a clinical stage biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announces its participation in three upcoming conferences in San Francisco, CA, USA, in January.
Turbine, a simulation-first drug discovery company, announced the formation of its Scientific Advisory Board with the appointments of Dr. Annalisa Jenkins, Dr. Mihriban Tuna, and Dr. Alan Barge.
Wellington Partners, a leading European venture capital firm investing in early- and growth-stage life science companies, announced that Dr. Karl Naegler joined Wellington as a Managing Partner on January 1, 2020.
New features are designed to improve chemiluminescence imaging workflow and quality
ProBioGen AG has signed a commercial license agreement with Roche for applying ProBioGen’s proprietary GlymaxX® technology to boost the antibody’s ADCC anti-tumor activity.
Adding cell types supports discovery of disease-modifying therapies for neurodegenerative diseases and triggers US$ 6M payment to Evotec
Test will specifically adjust for isatuximab-induced interference in complete response assessment of multiple myeloma patients
Pharma and biotech companies from across the globe provide business and pipeline updates.
Under the collaboration deal with Acerta, Veracyte will offer genomic information in support of Acerta’s oncology development program. Financial details were not disclosed.
PRESS RELEASES